Dr. Dhall will also direct the collection and dissemination of leukapheresis products for Re-MATC H Protocol Page 36 of 106 Version: 20180628 vaccine and T cell preparation to the University of Fl orida and the administration of vaccine products to subjects enrolled at CHLA. http://www.chla.org/site/apps/kb/cs/contactdisplay.as p?c=ipINKTOAJsG&b=3832751&sid=ewJXIjPWJfLYKd P1KzG&r=1 Mark Krieger, M.D. is Division Chief of Pediatric Neurosurgery and Director of the Neurosurgery Fellowship Program at CHLA. Dr. Krieger is a highly -experienced pediatric neurosurgeon at one of the top ranked pediatric hospitals in the nation. He will oversee the protocol compliant collection and dissemination of tumor materials suitable for vaccine preparation at the CHLA site and in his duties as Division Chief will ensure the proper pre - and post operative management of subjects enrolled on this protocol. Dr. Krieger will also ensure coordination of information with the Neurosurgical Chair of the protocol, Dr. Gerald Grant at Stanford University. http://www.chla.org/site/apps/kb/cs/contactdisplay.asp?c=ipINKTOAJsG&b=3832751&sid=dvKTKhPVIiI5If MQJrF&r=1 Clinical Research Staff: ANJELIKA M. DECHKOVSKAIA, M.D., Senior Biological Scientist , UF Brain Tumor Immunotherapy Program, Department of Neurosurgery, University of Florida CATHERINE FLORES, P h.D., Assistant Professor , UF Brain Tumor Immunotherapy Program, Department of Neurosurgery, University of Florida 4. STUDY LOCATION(S) UNIVERSITY OF FLORIDA HEALTH The sites for the routine and experimental care for patients enrolled on this study will be as follows: • Neurosurgical Care: Resections performed at UFHealth Shands Hospital , Pediatric Neurosurgeons • Consolidation chemotherapy and peripheral blood stem cell mobilization : UFHealth Shands Children’s Hospital, Supervising Physi cians: William Slayton, MD, and John R. Wingard, MD • Leuka pheresis and Stem Cell Harvest : UF Health Bone Marrow and Stem C ell Transplantation Clinics, Supervising Physician: John R. Wingard, M.D . • Dendritic cell generation, tumor RNA isolation and amplification, autologous T cell expansions : UF Brain Tumor Immunotherapy Program , Supervising Physician: Duane A. Mitchell, M.D., Ph.D. • High -dose chemotherapy and peripheral blood stem cell transplantation: UF Health Shands Children’s Hospital Bone and Stem Cell Transplantation Unit, Supervising Physicians : John R. Wingard M.D. , and William Slayton, MD • Autologous lymphocyte transfer and dendritic cell vaccinati on (inpatient) : UFHealth Shands Children’s Hospital Bone and Stem Cell Transplanta tion Unit , Supervising Physicians: John R. Wingard, M.D., and William Slayton , MD • Dendritic cell vaccination and follow -up visits (outpatient) : UF Health Pediatric Hematology/Oncology Clinic, Supervising Physicians : Duane A. Mitchell, M.D., Ph.D., William Slayton, MD, and John R. Wingard, MD • Immunologic monitoring and correlative assays : UF Brain Tumor Immunotherapy Program , Principal Investigator: Duane A. Mitchell, M.D., Ph.D. EXTERNAL SITES • Children’s National Medical Center Re-MATC H Protocol Page 37 of 106 Version: 20180628 • Children’s Hospital Los Angeles 5. TIME REQUIRED TO COM PLETE THE STUDY This protocol will be conducted under an FDA approved IND (IND BB -14058) covering the use of amplified tumor RNA pulsed DCs and adoptive lymphocyte transfer in patients with malignant brain tumors. University of Florida IRB and Institutional Biosafety Committee (IBC) reviews are completed and full -regulatory approval by these agencies is finalized . National Recombinant DNA Advisory Committee (RAC) review has been completed and a letter of approval/permission to proceed has been received. The projected ti me frame for th e phase I/II study is December 1, 201 0 through March 31, 201 9.